Eli Lilly and Company announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Christi Shaw has been hired to lead the company's Bio-Medicines business beginning April 3. Shaw will succeed Ricks, who became Lilly's president and CEO on January 1, as senior vice president and president of Lilly Bio-Medicines. Shaw, who started her career at Lilly in 1989, has more than 25 years of pharmaceutical and medical device experience. Beginning on February 1, Lilly's Diabetes, Oncology and Bio-Medicines human pharmaceutical therapeutic business areas will assume commercial responsibility for their products in China—in addition to the U.S., Japanese and Canadian markets in which they already operate. Sue Mahony, Ph.D., will continue as senior vice president of Lilly and president of Lilly Oncology. Alfonso (Chito) Zulueta, who has led the Emerging Markets business for the last three years, will be senior vice president of Lilly and president of Lilly International. Alex Azar, president of Lilly USA, has decided to leave Lilly to pursue other career opportunities.